Figure 6. Tumor immune microenvironment of patients in high- and low-risk groups with LUAD. (A) Immune scores. (B) Stromal scores. (C) Tumor purity between patients with high and low risk. (D) The expression of HLA genes between patients with high and low risk. (E) The difference in immune cell infiltration in different LUAD subtypes. (F) GO enrichment analyses. GO, gene ontology; HLA, human leukocyte antigen; LUAD, lung adenocarcinoma.